SCHEMBL199868

SCHEMBL199868

O=C(N=C=S)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
GSK3B P49841 2/20 0.42
SRD5A2 P31213 1/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484049 0.89 TP53 (0.35) CES2CES1TSHRGSK3BSRD5A2
SCHEMBL1029779 0.81 MAPT (0.46) CES2CA1CA2SRD5A2MAPK1
SCHEMBL3205731 0.81 CES2 (0.50) CES2CES1ALOX15TSHRCA1
SCHEMBL5242548 0.81 TSHR (0.52) CES2CES1ALOX15TSHRCA1
SCHEMBL572232 0.79 CES2 (0.48) CES2CES1CA1CA2LMNA
SCHEMBL5825164 0.79 TPMT (0.46) TSHRALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL2892447 0.79 ALDH1A1 (0.48) CES2CES1GSK3BSRD5A2MAPK1
SCHEMBL20258185 0.79 NOS3 (0.44) MAPK1LMNAL3MBTL1KDM4EALDH1A1
SCHEMBL5824636 0.79 TPMT (0.46) CA1CA2GSK3B
SCHEMBL2318580 0.79 CES2 (0.48) CES2CES1CA1CA2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors ORSOBIO INC (US) 2026-03-19 US disclosed
EP-4701635-A1 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS Universitat De Barcelona (ES) 2026-03-04 EP disclosed
WO-2024223907-A1 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS UNIVERSITAT DE BARCELONA (ES) 2024-10-31 WO disclosed
WO-2021137249-A1 A PROCESS FOR PREPARING 2-CHLORO-N-{[4-(PYRIMIDIN-2-YLSULFAMOYL)PHENYL] CARBAMOTHIOYL} BENZAMIDE AND THE PHARMACEUTICAL UTILITY THEREOF SOMADE PRAKASH MARUTI (IN) 2021-07-08 WO disclosed
WO-2021137249-A1 A PROCESS FOR PREPARING 2-CHLORO-N-{[4-(PYRIMIDIN-2-YLSULFAMOYL)PHENYL] CARBAMOTHIOYL} BENZAMIDE AND THE PHARMACEUTICAL UTILITY THEREOF SOMADE PRAKASH MARUTI (IN) 2021-07-08 WO disclosed
US-9675596-B2 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer BALTIC BIO AB (SE) 2017-06-13 US disclosed
EP-2200977-B1 F1F0-ATPASE INHIBITORS AND RELATED METHODS UNIV MICHIGAN (US) 2016-11-09 EP disclosed
US-20160128993-A1 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER BALTICGRUPPEN BIO AB (SE) 2016-05-12 US disclosed
EP-2451794-B1 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER BALTIC BIO AB (SE) 2016-01-27 EP disclosed
US-9221841-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2015-12-29 US disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 EP disclosed
EP-0424722-B1 Substituted (quinolin-2-yl-methoxy)phenyl-thioureas BAYER AG (DE) 1994-07-06 EP disclosed
US-5120744-A For combating diseases susceptible to the action of lipoxygenase inhibitors BAYER AKTIENGESELLSCHAFT (DE) 1992-06-09 US disclosed
US-5084457-A Cognition activators and nervous system disorders AMERICAN CYANAMID COMPANY (US) 1992-01-28 US disclosed
EP-0424722-A2 Substituted (quinolin-2-yl-methoxy)phenyl-thioureas BAYER AG (DE) 1991-05-02 EP disclosed
US-5001157-A Substituted N-[[2-(aminocarbonyl)phenylamino]thioxomethyl]benzamides AMERICAN CYANAMID COMPANY (US) 1991-03-19 US disclosed
US-4406897-A 6-Aryl-4-hydrazinyl-s-triazin-2-ones WILLIAM H. RORER, INC. (US) 1983-09-27 US disclosed
US-4367333-A PLASTICS CIBA-GEIGY CORPORATION (US) 1983-01-04 US disclosed
EP-0036389-A2 Metal complexes of isoindoline azines, process for their preparation and their use CIBA-GEIGY AG (CH) 1981-09-23 EP disclosed
US-4160037-A Compounds, compositions and methods of combatting pest employing thioureas THE UPJOHN COMPANY (US) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors CPT1B, CBR1, MUSK CES2 332/4885CES1 12/4885ALOX15 509/4885
US-20160128993-A1 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER HCCS, CCND3, MTNR1A CES2 3531/4885CES1 1158/4885ALOX15 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.